Edward H. Lin, MD
My major research focus has been on translational research on colon cancer stem cells. We were the first group that showed that elevated CD133 mRNA in the peripheral blood predict colon cancer relapse. We further showed that CD133 mRNA may be useful surrogate marker for treatment response. We were the first group that combined conventional chemotherapy agent e.g. capecitabine with stem cell inhibitor and found improved rate of complete remission and extended survival in patients with metastatic colorectal cancer. With Dr. Linheng Li, we were also the first group to propose ADAPT treatment concept targeting cancer stem cell. Our current focus will be will be on defining the molecular signatures of colon cancer patients successfully treated with ADAPT therapy. Our goal is to develop personalized treatment strategies that will minimize the evolution tumor to the current treatment.